Nutriband Inc.

NasdaqCM NTRB

Nutriband Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending October 31, 2024

Nutriband Inc. Capital Expenditure is NA for the Trailing 12 Months (TTM) ending October 31, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Nutriband Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending October 31, 2022 was USD -99.49 K.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqCM: NTRB

Nutriband Inc.

CEO	Mr. Gareth Sheridan
IPO Date	Oct. 1, 2021
Location	United States
Headquarters	121 South Orange Avenue
Employees	13
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Eyewear

Description

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Key trends

Past 5 years